Kfir Oved (0000-0003-3611-2218)

Personal information

No personal information available

Biography

I am a serial bioentrepreneur with >20 years of combined industry and academic experience, leading interdisciplinary teams combining Biotechnology, Applied Immunology, SW, Engineering, and Big Data in various medical applications including Therapeutics, Dx, Medical devices, and Digital Health. I co-founded MeMed Dx, served as its Chairman and CTO for over a decade, and led the inception, development, clinical validation, regulation, and manufacturing of the entire MeMed technology suite, including the MeMed BV™ technology, and the MeMed Key™ POC platform, from an idea on a napkin to development completion.

I hold a B.A. in Biology (Summa Cum Laude), a B.Sc. in medicine (Magna Cum Laude), a Ph.D. in molecular immunology, and six years of training at the Technion School of Medicine. I co-authored over 100 granted and pending patents, am the author of over 35 peer-reviewed publications, and received multiple research excellence awards, including the Gutwirth Excellence Award and Wolf Award for research students, and in 2019, I was listed as one of the top 25 voices in Precision Medicine. I was among the inceptors of the AI-based health data company Navina.ai and serve as its Chief Strategy Officer. In 2020, I founded Canopy Immuno-Therapeutics and serve as its CEO. Canopy is a stealth-mode biotech company engaged in the development of a novel, potentially curative immunotherapeutic approach for autoimmunity and life-threatening allergies.

Activities

Collapse all

Fighting AMR with Host Immune Response Technology

Drug Discovery Today

2021-09 | Journal article

DOI: 10.1016/j.drudis.2020.11.036

Part of ISSN: 1359-6446

Kfir Oved

https://orcid.org/0000-0003-3611-2218

Personal information

Biography

Activities

Works (35)

Fighting AMR with Host Immune Response Technology

An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome

Observational cohort study of IP-10’s potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19

Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation

1213. A TRAIL/IP-10/CRP Signature Distinguishes between Viral and Bacterial Infection in Chronic Obstructive Pulmonary Disease Patients

426. Use of Real Time IP-10 Measurements to Identify and Monitor the Dysregulated Immune Response in COVID-19 Patients

Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients

Unlocking the power of the host response to improve the management of infectious diseases

2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics

2624. Viral Pneumonia in Children: Facing the Challenge Using the Host Response

Expert panel diagnosis demonstrated high reproducibility as reference standard in infectious diseases

OC3 A host-response assay distinguishes between simple influenza patients and influenza patients with bacterial coinfection

Antibiotic misuse in respiratory tract infections in children and adults—a prospective, multicentre study (TAILORED Treatment)

Observational multi-centre, prospective study to characterize novel pathogen-and host-related factors in hospitalized patients with lower respiratory tract infections and/or sepsis - the “TAILORED-Treatment” study

1948. A Host-Response Assay Distinguishes Between Simple Influenza Patients and Influenza Patients With Bacterial Coinfection

1962. TRAIL Level and ImmunoXpert™ Score Complement Molecular Viral Detection in the Classification of Febrile Children: An Interim Analysis From the AutoPilotDx-Study

873. Using the Host Immune Response to Identify Viral-Bacterial Coinfection in Children With Respiratory Syncytial Virus Infection

Automating a new host-protein assay for differentiating bacterial from viral infection to reduce operator hands-on time

A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study

A novel host-protein assay outperforms routine parameters for distinguishing between bacterial and viral lower respiratory tract infections

Validation of a Novel Assay to Distinguish Bacterial and Viral Infections

A Novel Host-protein Assay Accurately Distinguishes Bacterial From Viral Upper Respiratory Tract Infections

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Protein as a Marker for Disease Severity in Patients With Acute Infection

Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules.

A multifaceted ‘omics’ approach for addressing the challenge of antimicrobial resistance

A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections

Antigen-Dependent Integration of Opposing Proximal TCR-Signaling Cascades Determines the Functional Fate of T Lymphocytes

Cover Picture: Eur. J. Immunol. 6/10

Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity

Predicting and controlling the reactivity of immune cell populations against cancer

Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.

A Novel Postpriming Regulatory Check Point of Effector/Memory T Cells Dictated through Antigen Density Threshold-Dependent Anergy

Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activityin vitro andin vivo

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenograftsin vivo